Abstract: The present invention relates to a process for producing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, including: coupling 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide to 2-phenylacetyl isothiocyanate.

Abstract: Provided is a c-Met inhibitory antitumor agent which mitigates side effects by selectively affecting tumor cells in which c-Met is specifically expressed, having a formula (I) or its salt: wherein each of R1 and R2 are independently a hydrogen atom, an optionally substituted C1-6 alkyl, C3-10 cycloalkyl, C6-14 aromatic hydrocarbon, or saturated or unsaturated heterocyclic group, or R1 and R2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R3 is a C1-6 alkyl group; and R4, R5, and R6, are independently a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R5 and R6 may form a ring together with the phenyl ring to which they are attached.

Abstract: To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed.

Abstract: The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RAR?, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): wherein X is N or CH; Y is O or S; R1, R2, and R3 are the same or different and are hydrogen or lower alkyl; R4 and R5 are the same or different and are hydrogen, lower alkyl, or halogen; and a bond between a carbon atom to which R1 is attached and a carbon atom to which R2 is attached is a single bond or a double bond; or a salt thereof.

Abstract: The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RAR?, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): wherein X is N or CH; Y is O or S; R1, R2, and R3 are the same or different and are hydrogen or lower alkyl; R4 and R5 are the same or different and are hydrogen, lower alkyl, or halogen; and a bond between a carbon atom to which R1 is attached and a carbon atom to which R2 is attached is a single bond or a double bond; or a salt thereof.

Abstract: The present invention provides a peptide derivative of formula (I) or a pharmaceutically acceptable salt thereof wherein X is —CH(OH)— or —CO—; R1 is hydrogen or an amino protecting group; R2 is hydroxyl or lower alkoxy; one of R3 and R4 is the side chain (R group) of lysine the amino group of which may be protected with a protecting group and the other of R3 and R4 is the side chain (R group) of arginine the guanidino group of which may be protected with a protecting group; and R5 and R6 may be the same or different and are hydrogen, lower alkyl or aralkyl. The present invention further provides a production process and use thereof.

Abstract: The present invention provides a peptide derivative of formula (I) wherein X is —CHOH— or —CO—; R1 and R2 are hydrogen or substituted oxycarbonyl; R3 is substituted oxycarbonyl; R4 is hydroxyl, lower alkoxy, optionally substituted piperazinyl or the like; R5 is a R-group side chain of an ?-amino acid optionally protected by a protective group, R6 is hydroxyl, lower alkoxy or the like; m is 0 or 1; and n is an integer of 2 to 6; or a pharmaceutically acceptable salt thereof. The present invention further provides a production process and use thereof.

Abstract: The present invention provides a peptide derivative of formula (I) or a pharmaceutically acceptable salt thereof 1

Abstract: The present invention provides a peptide derivative of formula (I) 1

Abstract: An indication device of the present invention includes a case body provided to a movable portion during in use by a both-sided adhesive tape or a fitting; luminous body provided with the case body and emits a light or a blinking light by using electric current generated in a power source; a first ON/OFF switch with an optical sensor interposed between the power source and luminous body, and a second ON/OFF switch turning on automatically during use. Therefore, the indication device can allow the others to become aware of person's whereabouts by emitting light or blinking light when in use. The device can be turned off automatically to prevent dissipation of power.

Abstract: The invention relates an epoxysuccinamide derivative represented by a formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl or aminoalkyl group, R.sup.2 represents an aminoalkyl group which May be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an aralkyl group which may be substituted, or an alkyl group substituted by a heterocyclic ring which may be substituted, or R.sup.1 and R.sup.2 may form a nitrogen-containing heterocyclic ring, which may be substituted, together with the adjacent nitrogen atoms, and R.sup.3 and R.sup.4 are the same or different from each other and independently represent a hydrogen atom, or an alkyl or aralkyl group, or a salt thereof, a preparation process thereof, and a medicine comprising such a derivative or salt as an active ingredient.

Abstract: The invention relates an epoxysuccinamide derivative represented by the general formula (1) ##STR1## wherein R.sup.1 and R.sup.2 are the same or different from each other and independently represent H or an aromatic hydrocarbon group or aralkyl group which may be substituted, or R.sup.1 and R.sup.2 may form a nitrogen-containing heterocyclic ring together with the adjacent nitrogen atoms, R.sup.3 is H or an acyl group, R.sup.4 is H or an aralkyl group, and R.sup.5 is an aromatic hydrocarbon group or aralkyl group which may be substituted, or R.sup.5 may form an amino acid residue, which may be protected, together with the adjacent nitrogen atom, or a salt thereof, and a medicine comprising the derivative as an active ingredient; and this compound has an inhibiting activity against cathepsin, and particularly, specifically inhibits cathepsin L and is hence useful for prevention and treatment of osteopathy such as osteoporosis.